Repligen projects 2026 revenue between $813M-$834M and raised EPS to $2.03-$2.09, following its BioLife deal.

This article provides an overview of significant business deals that occurred this week, featuring companies such as Stripe, IBM, Repligen, and LXP Industrial Trust.

This article evaluates Repligen Corporation (RGEN) as a potential investment opportunity. It offers insights into whether the biotechnology company's stock is currently a good buy.

Repligen (RGEN) stock experienced a drop following the release of its latest earnings report.

Repligen projects 2026 revenue between $803 million and $833 million, with an EPS forecast of $1.97-$2.05, and aims to increase its margin by one point by the end of 2027.

Several companies, including Repligen and HubSpot, have a track record of surpassing analysts' earnings estimates, which has historically led to an increase in their share prices.

Repligen (RGEN) has released the transcript of its Q4 2025 earnings call, providing details on the company's financial performance and outlook.

Repligen Corp. (RGEN) experienced a rise as industrial destocking decreased and order patterns stabilized, indicating a positive shift in its market conditions.

This article provides key highlights from Repligen's second-quarter earnings call, detailing financial performance and business updates.

Repligen announced its intention to acquire BioLife Solutions in a deal valued at $1.5 billion. This strategic acquisition aims to expand Repligen's presence and capabilities within the cell therapy market.

Repligen Corp. (RGEN) experienced a significant 28% decline in its stock value during the first quarter of the year.

Barclays has reiterated its 'Overweight' rating on Repligen Corporation (RGEN), indicating a positive outlook for the company's stock.

Thomson Reuters Corporation and Repligen Corporation both conducted their first-quarter 2026 earnings calls, summarizing their financial performance for the period.

Repligen Corp. experienced challenges in the first quarter, with tempered forward expectations negatively affecting the company's performance.

Repligen has set a 2026 revenue target between $810 million and $840 million, driven by the expansion of its analytics and protein franchises.

Repligen reported financial results that surpassed both top-line and bottom-line estimates, and also provided its outlook for fiscal year 2026.

Several companies, including Franklin Electric, CTS Corporation, and Oshkosh, have reported better-than-expected earnings and revenue, leading many to raise or reaffirm their financial outlooks for fiscal year 2026.

Repligen announced its intention to acquire BioLife Solutions in a $1.5 billion stock-and-cash deal. This acquisition aims to expand Repligen's cell therapy business.

BioLife Solutions is rumored to be a takeover target, with Repligen identified as a potential suitor, according to recent reports.

Yahoo Finance has published the earnings call transcript for Repligen (RGEN) for the first quarter of 2026.

Repligen has provided highlights from its fourth-quarter earnings call, offering an overview of its recent financial results.

A preview of Repligen's Q4 2025 earnings is available, highlighting key areas of focus for the upcoming release.